Levent Erdinç
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Levent Erdinç has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Nur Keleş
Dicle University
1 shared publication - Fesih Aktar
Department of Pediatrics, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
1 shared publication - Ilker Kelle
Department of Pharmacology, Faculty of Medicine, Dicle University, 21280 Diyarbakir, Turkey
1 shared publication - Mehmet Küçüköner
Department of Medical Oncology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
1 shared publication - Meral Erdinc
Department of Pharmacology, Faculty of Medicine, Dicle University, 21280 Diyarbakir, Turkey
1 shared publication - Meryem Seyda Kaya
Department of Pharmacology, Faculty of Pharmacy, Dicle University, 21280 Diyarbakir, Turkey
1 shared publication
Latest Publications
- Open Access
Protective Effects of Dabrafenib on Doxorubicin-Induced Cardiotoxicity in Rats
Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.
Open AccessProtective Effects of Dabrafenib on Doxorubicin-Induced Cardiotoxicity in Rats
Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.